BACKGROUND: The treatment of @entity1744 ( @entity1744 ) is a challenge because its cause remains unknown. Previous clinical trials to examine the efficacy of probiotic Bifidobacterium infantis 35624 ( @entity38349 ) in @entity1 with @entity1744 showed inconsistent findings. This study aimed to assess the combined effect of @entity38349 on reducing symptom severity of @entity1744 based on the published data. METHODS: A meta-analysis was conducted using fixed-effect models to estimate the combined effect of @entity38349 on primary outcomes, which included @entity490 , @entity11035 /distention, and bowel habit satisfaction. A systemic review was performed based on PubMed, Cochrane Library, and EMBASE databases to identify the randomized controlled trials comparing probiotics @entity38349 with placebo in treating @entity1744 symptoms, published up until December 31, 2016. Standardized mean differences (SMD) method was used to combine data since scales to measure the efficacy of probiotics were different among studies. RESULTS: A total of five studies were identified as suitable for inclusion, including three studies with single probiotic @entity38349 and two studies with composite probiotics containing @entity38349 . Treatment with single probiotic @entity38349 didn't impact on @entity490 , @entity11035 /distention, or bowel habit satisfaction among @entity1744 @entity1 . However, @entity1 who received composite probiotics containing @entity38349 significantly reduced @entity490 (SMD, 0.22; 95%CI, 0.03-0.41) and @entity11035 /distention (SMD, 0.30; 95%CI, 0.04-0.56). After combining the data from six studies, the improvement of @entity11035 /distention among @entity1744 @entity1 remained significant (SMD, 0.21; 95%CI, 0.07-0.35). CONCLUSION: Composite probiotics consisting of @entity38349 might be an effective therapeutic option to @entity1744 @entity1 , which could significantly alleviate the symptoms of @entity1744 without significant adverse effects. However, the efficacy of single probiotic @entity38349 on @entity1744 has not been confirmed yet, which needs to be further validated by more large-sized randomized clinical trials.

Efficacy of Bifidobacterium infantis 35624 in @entity1 with XXXX : a meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity38349 :: ('324767', 'Species') :: ['B. infantis'] @entity11035 :: ('MESH:C535647', 'Disease') :: ['bloating'] @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain'] @entity1744 :: ('MESH:D043183', 'Disease') :: ['irritable bowel syndrome', 'IBS']
@entity1744 :: (MESH:D043183,Disease) :: ['irritable bowel syndrome']
